MediciNova, Inc. has announced the successful completion of patient enrollment for the OXTOX study, a randomized, placebo-controlled Phase 2 clinical trial evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. The trial, led by Dr. Janette Vardy and Dr. Haryana Dhillon, enrolled 100 patients across two treatment arms at 11 clinical sites in Australia. Patient recruitment is now officially closed. Results from the study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604156) on December 18, 2025, and is solely responsible for the information contained therein.